Introduction Over the past decade, immuno-oncology (IO) has become one of the most promising and fastest-growing areas of cancer research and drug development. Present-day advances in immuno-oncology can be attributed to an explosion of research in this area in recent years, leading to a paradigm shift in the understanding of cancer. Until the late 1990s...
In recent years, immunotherapy has led to substantial advances in cancer therapy. In particular, the immune checkpoint inhibitors — PD-1/PD-L1 and CTLA-4 inhibitors — have revolutionized treatment for certain hematologic malignancies and solid tumors. The U.S. Food and Drug Administration (FDA) has approved six immunotherapies across 19 cancer types and two tissue-agnostic conditions. But widespread...
Oncology Expert Dr. Cassandra Matney Joins Global CRO DURHAM, N.C., August 3, 2020 — Premier Research continues to build its oncology expertise with the addition of Cassandra Matney, M.D., as Senior Medical Director. Matney joins a diversely talented team of oncology experts who have managed more than 170 oncology trials over the past five years....
DURHAM, N.C., SEPTEMBER 25, 2017 — Premier Research’s Chief Medical Officer will discuss development of immuno-oncology molecules at Outsourcing in Clinical Trials Southern California, September 27-28 in La Jolla. Dr. Colin Hayward will address strategic and practical considerations for molecule development on the opening day of the annual gathering of pharma, biotech, and medical device leaders....
As researchers seek to harness the human immune system to fight cancer, they’re looking at several emerging opportunities to expand use of biomarkers. Among them: Human leukocyte antigen typing. Microbiome analysis for determining risk of inflammatory complications with immune therapeutics. Tumor mutation burden, measured via whole genome sequencing, whole exome sequencing, or comprehensive gene panel...
Vaccines were once thought to have great potential for combating some types of cancer, but reality has failed to match those expectations. To date, vaccines have failed to play a major role in the pursuit of immune response for oncology patients. There have been two notable successes — sipuleucel-T (marketed as Provenge) is approved to...
In evaluating patient response to treatment of solid tumors, the nearly decade-old RECIST 1.1 guideline remains the gold standard. But the implementation earlier this year of the iRECIST guidance is focusing attention on how the many wide-ranging approaches to tumor assessment interrelate, and how they rank in relevance — today and looking forward. It all...
DURHAM, N.C., MAY 23, 2017 — Interleukin-2, interferon, and other immune-modulating agents have long been used to treat some solid malignancies, but their efficacy is generally limited to immunogenic cancers such as melanoma and kidney cancer. Until now. Today, multiple immuno-oncology pathways are under development, and we’ll explore this promising trend in a webinar on...